Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

2020 ◽  
Vol 134 ◽  
pp. 62-74 ◽  
Author(s):  
Patrick Schöffski ◽  
Olivier Mir ◽  
Bernd Kasper ◽  
Zsuzsanna Papai ◽  
Jean-Yves Blay ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Phase Ii ◽  
Kinase Inhibitor ◽  
Phase Ii Trial ◽  
Gastrointestinal Stromal Tumour ◽  
Stromal Tumour ◽  
European Organisation

scholarly journals Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

2017 ◽  
Vol 19 (11) ◽  
pp. 1522-1531 ◽  
Author(s):  
Juan Manuel Sepúlveda-Sánchez ◽  
María Ángeles Vaz ◽  
Carmen Balañá ◽  
Miguel Gil-Gil ◽  
Gaspar Reynés ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Phase Ii ◽  
Kinase Inhibitor ◽  
Phase Ii Trial ◽  
Recurrent Glioblastoma ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Amplification ◽  
Egfr Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document